Ebola Virus‐Like Particle–Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge
The Journal of Infectious Diseases2007Vol. 196(s2), pp. S430–S437
Citations Over TimeTop 10% of 2007 papers
Abstract
On the basis of safety and efficacy, eVLPs represent a promising filovirus vaccine for use in humans.
Related Papers
- → Contribution of Ebola Virus Glycoprotein, Nucleoprotein, and VP24 to Budding of VP40 Virus-Like Particles(2004)240 cited
- → High-resolution Crystal Structure of Dimeric VP40 FromSudan ebolavirus(2015)10 cited
- → Ebolavirus Replication and Tetherin/BST-2(2012)16 cited
- → Modeling Ebolavirus Budding with Virus Like Particles(2017)1 cited
- The Expression, Purification and Characterization of Ebola Virion Protein 24 and Karyopherin Alpha 5(2018)